We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Swedish Orphan Biovitrum (BIOVF - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Swedish Orphan Biovitrum is one of 1189 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Swedish Orphan Biovitrum is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BIOVF's full-year earnings has moved 12.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BIOVF has moved about 4% on a year-to-date basis. In comparison, Medical companies have returned an average of -12%. This shows that Swedish Orphan Biovitrum is outperforming its peers so far this year.
EDAP TMS S.A. (EDAP - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 18.7%.
For EDAP TMS S.A. the consensus EPS estimate for the current year has increased 6.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Swedish Orphan Biovitrum belongs to the Medical - Biomedical and Genetics industry, which includes 558 individual stocks and currently sits at #72 in the Zacks Industry Rank. On average, this group has lost an average of 18.1% so far this year, meaning that BIOVF is performing better in terms of year-to-date returns.
EDAP TMS S.A. however, belongs to the Medical - Instruments industry. Currently, this 104-stock industry is ranked #80. The industry has moved -24.8% so far this year.
Swedish Orphan Biovitrum and EDAP TMS S.A. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Swedish Orphan Biovitrum (BIOVF - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Swedish Orphan Biovitrum is one of 1189 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Swedish Orphan Biovitrum is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BIOVF's full-year earnings has moved 12.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BIOVF has moved about 4% on a year-to-date basis. In comparison, Medical companies have returned an average of -12%. This shows that Swedish Orphan Biovitrum is outperforming its peers so far this year.
EDAP TMS S.A. (EDAP - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 18.7%.
For EDAP TMS S.A. the consensus EPS estimate for the current year has increased 6.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Swedish Orphan Biovitrum belongs to the Medical - Biomedical and Genetics industry, which includes 558 individual stocks and currently sits at #72 in the Zacks Industry Rank. On average, this group has lost an average of 18.1% so far this year, meaning that BIOVF is performing better in terms of year-to-date returns.
EDAP TMS S.A. however, belongs to the Medical - Instruments industry. Currently, this 104-stock industry is ranked #80. The industry has moved -24.8% so far this year.
Swedish Orphan Biovitrum and EDAP TMS S.A. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.